Emerging biomaterials for tumor immunotherapy
Source abstract
Abstract
Abstract Background The immune system interacts with cancer cells in various intricate ways that can protect the individual from overproliferation of cancer cells; however, these interactions can also lead to malignancy. There has been a dramatic increase in the application of cancer immunotherapy in the last decade. However, low immunogenicity, poor specificity, weak presentation efficiency, and off-target side effects still limit its widespread application. Fortunately, advanced biomaterials effectively contribute immunotherapy and play an important role in cancer treatment, making it a research hotspot in the biomedical field. Main body This review discusses immunotherapies and the development of related biomaterials for application in the field. The review first summarizes the various types of tumor immunotherapy applicable in clinical practice as well as their underlying mechanisms. Further, it focuses on the types of biomaterials applied in immunotherapy and related research on metal nanomaterials, silicon nanoparticles, carbon nanotubes, polymer nanoparticles, and cell membrane nanocarriers. Moreover, we introduce the preparation and processing technologies of these biomaterials (liposomes, microspheres, microneedles, and hydrogels) and summarize their mechanisms when applied to tumor immunotherapy. Finally, we discuss future advancements and shortcomings related to the application of biomaterials in tumor immunotherapy. Conclusion Research on biomaterial-based tumor immunotherapy is booming; however, several challenges remain to be overcome to transition from experimental research to clinical application. Biomaterials have been optimized continuously and nanotechnology has achieved continuous progression, ensuring the development of more efficient biomaterials, thereby providing a platform and opportunity for breakthroughs in tumor immunotherapy. Graphical Abstract
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Otorhinolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China.
Department of Hemodialysis, the Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China.
State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China.
Funding
National Natural Science Foundation of China · Natural Science Foundation of Hunan Province
References (100+)
Show source-provided references
1. 10.1097/CM9.000000000000210810.1097/CM9.0000000000002108 ↗
2. 10.4155/tde.13.8810.4155/tde.13.88 ↗
3. 10.1016/j.cell.2019.01.00810.1016/j.cell.2019.01.008 ↗
4. 10.1002/advs.20220002710.1002/advs.202200027 ↗
5. 10.2147/DDDT.S30857810.2147/DDDT.S308578 ↗
6. 10.1038/s41423-020-0481-010.1038/s41423-020-0481-0 ↗
7. 10.1038/s41416-018-0328-y10.1038/s41416-018-0328-y ↗
8. 10.1038/s41568-021-00363-z10.1038/s41568-021-00363-z ↗
9. 10.1038/s41423-021-00786-610.1038/s41423-021-00786-6 ↗
10. Eno J. Immunotherapy through the years. J Adv Pract Oncol. 2017;8:747–753.
11. 10.3389/fimmu.2022.87201010.3389/fimmu.2022.872010 ↗
12. 10.3389/fimmu.2018.0290510.3389/fimmu.2018.02905 ↗
13. Hansen RM, Borden EC. Current status of interferons in the treatment of cancer. Oncology (Williston Park). 1992;6:19–24. 1:STN:280:DyaK3s%2FnsFKjug%3D%3D. discussion 26, 29.
14. 10.1111/1523-1747.ep1287578910.1111/1523-1747.ep12875789 ↗
15. 10.1186/s40164-017-0081-610.1186/s40164-017-0081-6 ↗
16. 10.1126/science.aaa817210.1126/science.aaa8172 ↗
17. 10.1038/s41571-021-00588-910.1038/s41571-021-00588-9 ↗
18. 10.1053/j.seminoncol.2014.08.00310.1053/j.seminoncol.2014.08.003 ↗
19. 10.3233/HAB-2009-020410.3233/HAB-2009-0204 ↗
20. 10.2165/11531280-000000000-0000010.2165/11531280-000000000-00000 ↗
21. 10.1038/d41573-021-00079-710.1038/d41573-021-00079-7 ↗
22. 10.1038/nrc393010.1038/nrc3930 ↗
23. 10.1016/j.pharmthera.2017.12.00210.1016/j.pharmthera.2017.12.002 ↗
24. 10.2147/DDDT.S15128210.2147/DDDT.S151282 ↗
25. 10.1080/19420862.2020.172534610.1080/19420862.2020.1725346 ↗
26. 10.1038/s41392-021-00670-910.1038/s41392-021-00670-9 ↗
27. 10.1016/j.pharmthera.2019.04.00610.1016/j.pharmthera.2019.04.006 ↗
28. 10.1016/S0140-6736(22)01654-310.1016/S0140-6736(22)01654-3 ↗
29. 10.1136/bmjopen-2021-05839610.1136/bmjopen-2021-058396 ↗
30. 10.1016/S2666-7568(22)00116-710.1016/S2666-7568(22)00116-7 ↗
31. 10.1016/j.annonc.2021.06.02410.1016/j.annonc.2021.06.024 ↗
32. 10.1111/imm.1203610.1111/imm.12036 ↗
33. 10.1038/nm.356010.1038/nm.3560 ↗
34. 10.1111/febs.1365610.1111/febs.13656 ↗
35. 10.1038/s41551-021-00799-610.1038/s41551-021-00799-6 ↗
36. Abdin SM Zaher DM Arafa EA Omar HA. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. Cancers (Basel). 2018;10(2):32.10.3390/cancers10020032 ↗
37. He CH, Li XM. Research progress in immunotherapy of head and neck squamous cell carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022;57:82–88. 1:STN:280:DC%2BB2M7kt1aqsQ%3D%3D
38. 10.3389/fphar.2017.0056110.3389/fphar.2017.00561 ↗
39. 10.1016/S1470-2045(17)30607-110.1016/S1470-2045(17)30607-1 ↗
40. 10.1634/theoncologist.2015-049810.1634/theoncologist.2015-0498 ↗
41. 10.1634/theoncologist.2017-008710.1634/theoncologist.2017-0087 ↗
42. Wei W Ban X Yang F Li J Cheng X Zhang R Huang X Huang Y Li Q Qiu Y Zheng M Zhu X Li J. Phase II trial of efficacy safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer. J Immunother Cancer. 2022;10(5):e004338.10.1136/jitc-2021-004338 ↗
43. 10.1200/JCO.21.0209110.1200/JCO.21.02091 ↗
44. 10.1016/j.jtho.2020.11.02610.1016/j.jtho.2020.11.026 ↗
45. 10.3389/fonc.2022.90903510.3389/fonc.2022.909035 ↗
46. 10.1186/s12916-022-02605-910.1186/s12916-022-02605-9 ↗
47. 10.3389/fonc.2021.67327610.3389/fonc.2021.673276 ↗
48. 10.3389/fimmu.2020.0017610.3389/fimmu.2020.00176 ↗
49. 10.1136/dtb.2020.00004010.1136/dtb.2020.000040 ↗
50. 10.1002/cti2.127410.1002/cti2.1274 ↗
51. 10.1177/153303381983106810.1177/1533033819831068 ↗
52. 10.1186/s40425-016-0164-710.1186/s40425-016-0164-7 ↗
53. 10.1002/mco2.4110.1002/mco2.41 ↗
54. 10.1126/science.abb984710.1126/science.abb9847 ↗
55. 10.1007/s00120-017-0338-z10.1007/s00120-017-0338-z ↗
56. 10.1126/science.aar324610.1126/science.aar3246 ↗
57. Maeng HM Berzofsky JA. Strategies for developing and optimizing cancer vaccines. F1000Res. 2019;8:F1000 Faculty Rev-654.10.12688/f1000research.18693.1 ↗
58. 10.1158/1078-0432.CCR-10-312610.1158/1078-0432.CCR-10-3126 ↗
59. 10.1080/14760584.2018.143400010.1080/14760584.2018.1434000 ↗
60. 10.1016/j.imlet.2018.01.01110.1016/j.imlet.2018.01.011 ↗
61. Waki K, Yamada A. Personalized peptide vaccine for cancer treatment; now and its future. Nihon Rinsho. 2017;75:251–256.
62. 10.1186/s12943-019-1055-610.1186/s12943-019-1055-6 ↗
63. 10.1007/s11033-022-07525-810.1007/s11033-022-07525-8 ↗
64. 10.3389/fimmu.2022.88537110.3389/fimmu.2022.885371 ↗
65. 10.3389/fimmu.2022.100068110.3389/fimmu.2022.1000681 ↗
66. 10.1111/cas.1302710.1111/cas.13027 ↗
67. 10.1038/s41577-018-0014-610.1038/s41577-018-0014-6 ↗
68. Zhang B Huang J Tang J Hu S Luo S Luo Z Zhou F Tan S Ying J Chang Q Zhang R Geng C Wu D Gu X Liu B. Intratumoral OH2 an oncolytic herpes simplex virus 2 in patients with advanced solid tumors: a multicenter phase I/II clinical trial. J Immunother Cancer. 2021;9(4):e002224.10.1136/jitc-2020-002224 ↗
69. 10.1016/j.ygyno.2021.10.06910.1016/j.ygyno.2021.10.069 ↗
70. 10.1038/s41467-021-22929-z10.1038/s41467-021-22929-z ↗
71. 10.1093/annonc/mds26210.1093/annonc/mds262 ↗
72. Gellrich FF Schmitz M Beissert S Meier F. Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update. J Clin Med. 2020;9(1):223.10.3390/jcm9010223 ↗
73. 10.1155/2019/524503410.1155/2019/5245034 ↗
74. 10.1186/s13045-021-01164-510.1186/s13045-021-01164-5 ↗
75. 10.1039/C8BM01470A10.1039/C8BM01470A ↗
76. 10.1002/anie.20200278010.1002/anie.202002780 ↗
77. 10.1002/mco2.810.1002/mco2.8 ↗
78. 10.1016/j.biomaterials.2018.05.05110.1016/j.biomaterials.2018.05.051 ↗
79. 10.1002/advs.20190003710.1002/advs.201900037 ↗
80. 10.1021/acsami.7b1121910.1021/acsami.7b11219 ↗
81. 10.1039/C8NR08704K10.1039/C8NR08704K ↗
82. 10.1186/s11671-018-2661-810.1186/s11671-018-2661-8 ↗
83. 10.1021/acs.molpharmaceut.7b0110310.1021/acs.molpharmaceut.7b01103 ↗
84. 10.1002/adhm.20220093810.1002/adhm.202200938 ↗
85. 10.1021/acs.jmedchem.2c0135110.1021/acs.jmedchem.2c01351 ↗
86. 10.1016/j.nano.2020.10233310.1016/j.nano.2020.102333 ↗
87. 10.1016/j.actbio.2022.08.07310.1016/j.actbio.2022.08.073 ↗
88. 10.1016/j.bioadv.2022.21286710.1016/j.bioadv.2022.212867 ↗
89. Qiang N Wei L Tao Y Jin W Bin Y DingHua Z. Construction of Durvalumab/carbon nanotube/PEI/aptamer-siRNA chimera for the immunotherapy of hepatocellular carcinoma. Biomed Mater. 2022;17(2). https://doi.org/10.1088/1748-605X/ac5414.10.1088/1748-605X/ac5414 ↗
90. 10.1002/open.20190012610.1002/open.201900126 ↗
91. 10.1166/jbn.2018.260510.1166/jbn.2018.2605 ↗
92. 10.1016/j.vaccine.2009.10.15310.1016/j.vaccine.2009.10.153 ↗
93. 10.1021/acs.biomac.5b0115010.1021/acs.biomac.5b01150 ↗
94. 10.1016/j.ejpb.2019.04.00710.1016/j.ejpb.2019.04.007 ↗
95. 10.1038/ncomms1319310.1038/ncomms13193 ↗
96. Zhu Y, Yang Z, Dong Z, Gong Y, Hao Y, Tian L, Yang X, Liu Z, Feng L. CaCO(3)-Assisted Preparation of pH-responsive immune-modulating nanoparticles for augmented chemo-immunotherapy. Nanomicro Lett. 2020;13:29.
97. 10.1038/s41467-021-23244-310.1038/s41467-021-23244-3 ↗
98. 10.3389/fimmu.2022.88764910.3389/fimmu.2022.887649 ↗
99. 10.1038/s41563-022-01251-z10.1038/s41563-022-01251-z ↗
100. 10.1016/j.ijpharm.2022.12195310.1016/j.ijpharm.2022.121953 ↗